ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

Comparative Study of Sevelamer Carbonate and Calcium Carbonate on Fibroblast Growth Factor-23 and Parathyroid Hormone in Hemodialysis Iraqi Patients

Journal: International Journal of Science and Research (IJSR) (Vol.3, No. 5)

Publication Date:

Authors : ; ; ; ;

Page : 1407-1411

Keywords : Sevelamer carbonate; Calcium carbonate; Fibroblast growth factor-23;

Source : Downloadexternal Find it from : Google Scholarexternal


Fibroblast growth factor-23, play an important role in atherosclerosis, endothelial dysfunction and vascular calcification. Sevelamer can improve vascular calcification, serum uric acid, low-density lipoprotein -cholesterol and Fibroblast growth factor-23. Aim of study Assesment the effect of sevelamer as phosphate binder against calcium carbonate on Fibroblast growth factor-23. Methods A prospective open- labelled study that included patients on hemodialysis. A total of 72 patients were screened, only 53 patients completed the 10 week period. Adults patients with serum phosphate as greater than5.5 mg/dl were included. There were Group1 Includes 28 patients (19 males and 9 females receiving sevelamer carbonate (Renvela) tablet. Group 2 Include 25patients (17 male and 8 female) receiving calcium carbonate tablet. Level of serum calcium, phosphorus, albumin, at pre wash, baseline and every 5 weeks, meanwhile the Level Low-density lipoprotein, Fibroblast growth factor23, and parathyroid hormone were measured at baseline and after 10 weeks. ResultsSerum phosphorus was significantly reduced after 10 weeks with both sevelamer carbonate -22.4 % and calcium carbonate -23.5 %. Serum parathyroid was significantly reduced in both groups. Only group 1 was associated with significant reduction in low-density lipoprotein cholesterol by 26.4 % from base line, significant reduction in Fibroblast growth factor-23 level by -31.2 % and significant decrease in Calcium phosphate product -29.5 %. Significant rise in the serum calcium in group 2 patients (14.34 %). ConclusionSevelamer superior to calcium-based binders in reducing hypercalcemia and Calcium phosphate product which decrease intimal calcification of dialysis patient arteries, and favorable reduction in Fibroblast growth factor 23, and low-density lipoprotein cholesterol in dialysis patients.

Last modified: 2021-06-30 19:59:36